Company · founded 2003

Affinergy (United States)

Durham, United States · affinergy.com

Manage this page

Citations, last 5 years: 0
Works, last 5 years: 0
h-index: 14
Scientists listed: 0
Grants since 2016: 40

Grants received

2023–2025 · research · R44

A novel peptide assay for hepcidin clinical monitoring

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$613.8kIron Metabolism and Disorders

2023–2025 · research · R44

A novel peptide assay for hepcidin clinical monitoring

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$590.9kIron Metabolism and Disorders

2021–2023 · research · R43

Novel clinical assay to rapidly monitor posaconazole levels in plasma

Jonathan A Hodges · Affinergy (United States) · funded by National Institutes of Health

$294.5kAntifungal resistance and susceptibility

2021–2023 · research · R44

A Rapid Point of Care Test for APOL1 Renal Risk Alleles

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$685kRenal Diseases and Glomerulopathies

2021–2024 · research · R44

A Rapid Point of Care Test for APOL1 Renal Risk Alleles

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$741.4kRenal Diseases and Glomerulopathies

2020–2024 · research · R44

Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$682.8kAntimicrobial Resistance in Staphylococcus

2020–2023 · research · R44

Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$590.2kAntimicrobial Resistance in Staphylococcus

2020–2021 · research · R43

Immunoprofiling to develop a novel diagnostic array for cardiac sarcoidosis

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$299.8kSarcoidosis and Beryllium Toxicity Research

2020–2023 · research · R44

Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$679.4kAntimicrobial Resistance in Staphylococcus

2020–2021 · research · R43

Development of a peptide-based diagnostic for amyotrophic lateral sclerosis

Shrikumar Ambujakshan Nair · Affinergy (United States) · funded by National Institutes of Health

$299.8kAmyotrophic Lateral Sclerosis Research

2019–2023 · research · R44

Development of a novel clinical assay for measuring everolimus levels

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$648.9kRenal Transplantation Outcomes and Treatments

2019–2020 · research · R44

Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$283.2kAntimicrobial Resistance in Staphylococcus

2019–2022 · research · R44

Development of a novel clinical assay for measuring everolimus levels

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$744kRenal Transplantation Outcomes and Treatments

2019–2022 · research · R44

Development of a novel clinical assay for measuring everolimus levels

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$717.6kRenal Transplantation Outcomes and Treatments

2019–2020 · research · R43

Development of a multiplex peptide array to identify patients with an autoantibody signature for chronic pain

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$320.1k

2019–2021 · research · R43

Development of a multiplex point-of-care assay to identify patients with Venous Thromboembolism

Shrikumar Ambujakshan Nair · Affinergy (United States) · funded by National Institutes of Health

$297.4k

2018–2019 · research · R43

A point-of-care assay to monitor tobramycin in cystic fibrosis patients

Shrikumar Ambujakshan Nair · Affinergy (United States) · funded by National Institutes of Health

$299.6kCystic Fibrosis Research Advances

2018–2020 · research · R43

Autoantibody profiling to develop a novel diagnostic array for systemic sclerosis

Jonathan A Hodges · Affinergy (United States) · funded by National Institutes of Health

$299.2kSystemic Sclerosis and Related Diseases

2018–2019 · research · R44

Novel assay to monitor Tacrolimus levels at the point of care

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$300kRenal Transplantation Outcomes and Treatments

2018–2019 · research · R43

A novel clinical assay for detection of APOL1 renal risk alleles

Jonathan A Hodges · Affinergy (United States) · funded by National Institutes of Health

$320kRenal Diseases and Glomerulopathies

2018–2022 · research · R44

Novel assay to monitor Tacrolimus levels at the point of care

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$734.1kRenal Transplantation Outcomes and Treatments

2018–2022 · research · R44

Novel assay to monitor Tacrolimus levels at the point of care

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$759.3kRenal Transplantation Outcomes and Treatments

2018–2023 · research · R44

Novel assay to monitor Tacrolimus levels at the point of care

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$735kRenal Transplantation Outcomes and Treatments

2017–2018 · research · R43

Point-of-care device to identify patients at risk for preeclampsia

Shrikumar Ambujakshan Nair · Affinergy (United States) · funded by National Institutes of Health

$200kPregnancy and preeclampsia studies

2017–2018 · research · R43

Point-of-care device to identify patients at risk for preeclampsia

Shrikumar Ambujakshan Nair · Affinergy (United States) · funded by National Institutes of Health

$52.2kPregnancy and preeclampsia studies

2017–2018 · research · R43

Novel PhageLock assay to measure hepcidin for clinical monitoring

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$333kIron Metabolism and Disorders

2017–2018 · research · R43

Peptide-based tool for the rapid isolation of quiescent monocytes from peripheral blood

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$308.8kImmunotherapy and Immune Responses

2017–2021 · research · R44

Point-of-care device to identify patients at risk for preeclampsia

Shrikumar Ambujakshan Nair · Affinergy (United States) · funded by National Institutes of Health

$752.9kPregnancy and preeclampsia studies

2017–2021 · research · R44

Point-of-care device to identify patients at risk for preeclampsia

Shrikumar Ambujakshan Nair · Affinergy (United States) · funded by National Institutes of Health

$85.3kPregnancy and preeclampsia studies

2017–2023 · research · R44

Point-of-care device to identify patients at risk for preeclampsia

Jonathan A Hodges · Affinergy (United States) · funded by National Institutes of Health

$702.1kPregnancy and preeclampsia studies

2017–2021 · research · R44

Point-of-care device to identify patients at risk for preeclampsia

Shrikumar Ambujakshan Nair · Affinergy (United States) · funded by National Institutes of Health

$736.2kPregnancy and preeclampsia studies

2016–2020 · research · R44

Novel technologies for detection of podocytes from preeclamptic patients

Shrikumar Ambujakshan Nair · Affinergy (United States) · funded by National Institutes of Health

$707.8kPregnancy and preeclampsia studies

2016–2021 · research · R44

Novel technologies for detection of podocytes from preeclamptic patients

Shrikumar Ambujakshan Nair · Affinergy (United States) · funded by National Institutes of Health

$653.5kPregnancy and preeclampsia studies

2016–2017 · research · R43

Peptide-based slides for improving the diagnostic quality of sputum specimens

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$300k

2016–2018 · research · R43

Novel technologies for improved slide quality of pancreatic fine-needle aspirates

Shrikumar Ambujakshan Nair · Affinergy (United States) · funded by National Institutes of Health

$301k

2016–2020 · research · R44

Novel technologies for detection of podocytes from preeclamptic patients

Shrikumar Ambujakshan Nair · Affinergy (United States) · funded by National Institutes of Health

$638.7kPregnancy and preeclampsia studies

2016–2017 · research · R43

Novel technologies for the detection of podocytes from preeclamptic patients

Shrikumar Ambujakshan Nair · Affinergy (United States) · funded by National Institutes of Health

$300kPregnancy and preeclampsia studies

2014–2020 · research · R44

Novel technologies to remove obscuring blood from fine needle aspiration biopsies

Shrikumar Ambujakshan Nair · Affinergy (United States) · funded by National Institutes of Health

$697k

2014–2020 · research · R44

Novel technologies to remove obscuring blood from fine needle aspiration biopsies

Shrikumar Ambujakshan Nair · Affinergy (United States) · funded by National Institutes of Health

$203.6k

2014–2021 · research · R44

Stem cell-binding peptides for rapid fixation of total hip replacements

Martyn Darby · Affinergy (United States) · funded by National Institutes of Health

$746.3k